抗VEGF治疗假性糖尿病性黄斑水肿眼治疗模式的回顾性分析,Journal of Ophthalmology

当前位置： X-MOL 学术 › J. Ophthalmol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

抗VEGF治疗假性糖尿病性黄斑水肿眼治疗模式的回顾性分析
Journal of Ophthalmology ( IF 1.8 ) Pub Date : 2021-07-28 , DOI: 10.1155/2021/9967831
Di Zou ₁ , Imran Jawaid ₁ , Winfried M Amoaku _{1,

2}

Affiliation

背景/目标。目前，在英国，抗血管内皮生长因子 (anti-VEGF) 是中央黄斑厚度 (CMT) ≥400 微米的糖尿病性黄斑水肿 (DMO) 的一线治疗药物。在对一线治疗反应不佳的假晶状体眼中，也可以使用玻璃体内皮质类固醇。在实践中，尽管进行了严格的抗 VEGF 治疗，但近一半的 DMO 患者的反应并不理想。本研究的目的是调查结构和功能结果，并检查在接受 DMO 抗 VEGF 注射的假晶状体眼中的抗 VEGF 治疗递送。方法. 我们对接受至少 6 次抗 VEGF 注射的 81 只 DMO 假晶状体眼的结果进行了回顾性分析。我们回顾了基线和治疗后的光学相干断层扫描图像、视力、处方模式、提供抗 VEGF 注射所需的时间以及结构和功能结果。结果。平均需要 913 ± 454.1 天才能进行平均 11.1 ± 4.7 次抗 VEGF 注射。在 74.7% ( n = 59/79) 的眼睛中，从基线到接受前 6 次抗 VEGF 注射的时间超过 9 个月。从基线到终点平均增加了 1.6 个字母（-0.03 logMAR）。玻璃体内注射 5 次抗 VEGF 后，平均 CMT 为 391.9 μm ，基线时为 474.4 μm（）。在 79 只眼中的 52 只眼（65.8%）中，使用了一种以上的抗 VEGF 药物。结论。用于用 DMO 治疗这些眼睛的抗 VEGF 治疗效果不佳，这一发现与最近公布的“真实世界”数据一致。患者强烈倾向于在该类别中转换为第二种抗 VEGF 药物。

"点击查看英文标题和摘要"

Retrospective Analysis of Treatment Patterns in Pseudophakic Diabetic Macular Oedema Eyes Treated with Anti-VEGF

Background/Objectives. Currently, in England, antivascular endothelial growth factor (anti-VEGF) is the first-line treatment for diabetic macular oedema (DMO) where central macular thickness (CMT) is ≥400 microns. In pseudophakic eyes with suboptimal response to first-line therapy, intravitreal corticosteroids may also be used. In practice, despite rigorous anti-VEGF therapy, suboptimal response occurs in nearly half of all eyes with DMO. The objective of this study was to investigate structural and functional outcomes and examine anti-VEGF treatment delivery in pseudophakic eyes receiving anti-VEGF injections for DMO. Methods. We performed a retrospective review of outcomes in 81 pseudophakic eyes with DMO that received at least 6 anti-VEGF injections. We reviewed baseline and posttreatment optical coherence tomography images, visual acuity, prescribing patterns, time taken to deliver anti-VEGF injections, and structural and functional outcomes. Results. It took an average of 913 ± 454.1 days to deliver a mean of 11.1 ± 4.7 anti-VEGF injections. Time from baseline to receiving the first 6 anti-VEGF injections was longer than 9 months in 74.7% (n = 59/79) of eyes. There was a mean gain of 1.6 letters (−0.03 logMAR) from baseline to the end point. After 5 anti-VEGF intravitreal injections, the mean CMT was 391.9 μm from 474.4 μm at baseline (). In 52 of 79 eyes (65.8%), more than one type of anti-VEGF agent was used. Conclusions. The anti-VEGF treatment used to treat these eyes with DMO was suboptimal, a finding consistent with recently published “real-world” data. There was a strong tendency for patients to be switched within the class to a second anti-VEGF agent.

更新日期：2021-07-28

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南